2025 년 대한면역학회 춘계학술대회

2025 년 4월 10일(목) - 11일(금) | 세종대학교 컨벤션센터 광개토관

C.V.

Full Name	Ji Yun Noh
Organization	Korea University
Position & Title	Professor

Educational background & professional experience (in sequence of the latest year)

- 2009~2013 PhD in Microbiology, Korea Univ. Graduate School
- 2007~2009 MS in Internal Medicine, Korea Univ. Graduate School
- 1999~2005 MD, Korea Univ. College of Medicine
- 2024~ Professor, Division of Infectious Diseases, Department of Internal Medicine, Korea University Guro Hospital, Korea Univ. College of Medicine
- 2021~2022 Visiting professor, KAIST Graduate School of Medical Science and Engineering
- 2019~2024 Associate professor, Division of Infectious Diseases, Department of Internal Medicine, Korea University Guro Hospital, Korea Univ. College of Medicine
- 2013~2019 Assistant professor, Division of Infectious Diseases, Department of Internal Medicine, Korea University Guro Hospital, Korea Univ. College of Medicine

Research Interests

SARS-CoV-2, influenza, herpes zoster, vaccine

Publications

- 1) Kim SH, Kim J, Jung S, Noh JY et al. Omicron BA.2 breakthrough infection elicits CD8+ T cell responses recognizing the spike of later Omicron subvariants. Sci Immunol . 2024 Jan 19;9(91):eade6132. doi: 10.1126/sciimmunol.ade6132.
- 2) Jung MK, Jeong SD, Noh JY et al. BNT162b2-induced memory T cells respond to the Omicron variant with preserved polyfunctionality. Nat Microbiol. 2022 May 16. doi: 10.1038/s41564-022-01123-x
- 3) Noh JY, Yang JS et al. Duration of humoral immunity and cross-neutralizing activity against the Alpha, Beta, and Delta variants after wild-type SARS-CoV-2 infection: A prospective cohort study. J Infect Dis. 2022 Feb 16;jiac050. doi: 10.1093/infdis/jiac050.
- 4) Noh JY et al. T cell-oriented strategies for controlling the COVID-19 pandemic. Nat Rev Immunol. 2021;21:687-688.

Short biography

As a clinician in the infectious diseases, my current research interests include but are not limited to the immune response to the respiratory viruses including influenza virus and SARS-CoV-2 and varicella-zoster virus, immunogenicity of vaccines, and vaccine clinical trial.